for orders over $200
Toremifene (TOR) is a second-generation selective estrogen receptor modulator (SERM) that is primarily used to treat hormone receptor-positive breast cancer in postmenopausal women. It binds to estrogen receptors in breast tissues and interferes with the growth and proliferation of cancer cells. It is a chlorinated derivative of tamoxifen (TAM) and is equally effective in treating breast cancer.
Toremifene was first approved by the FDA in 1997 for the first-line treatment of estrogen receptor-positive breast cancer or unknown metastatic cancer in postmenopausal women. It has also been shown to have effects on bone mineral density and lipid profiles. At Element Sarms, toremifene purchase is restricted to educational and research purposes.
IUPAC Name:2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamineSynonyms: Acapodene, Farestone, Z-ToremifeneMolecular Formula: C26H28ClNOMolecular Weight: 406.0 g/molCAS Number: 89778-26-7PubChem CID: 3005573
Toremifene has been widely used to treat hormone receptor-positive breast cancer in both early and late stages. Its efficacy has been well established by nine prospective randomized phase III trials. The results of these studies show that toremifene has an equivalent efficacy to tamoxifen but has a slightly better side effect profile. TOR is less likely to cause vascular events and uterine neoplasms and has a better effect on serum lipid levels .
Furthermore, toremifene has a different pharmacokinetic profile as compared to tamoxifen. Tamoxifen is a prodrug that is converted into its active metabolites by CYP2D6 isoenzymes. However, Toremifene doesn’t require enzymatic conversion by CYP2D6 for its activity. Studies show that genetic polymorphism within CYP2D6 affects the interindividual response to tamoxifen and toremifene might be an adjuvant alternative endocrine therapy for patients with CYP2D6*10 mutant genotype .
Toremifene has been shown to increase bone mineral density and prevent fracture. In a randomized phase III trial, men with prostate cancer on androgen deprivation therapy were randomized to receive toremifene (80mg/day) or placebo. The results found that toremifene significantly increased bone mineral density of the hip and spine . Another study found that it significantly reduced the risk of new vertebral fractures by 79.5% in men younger than 80 years. Plus, it decreased bone loss by 7% and increased bone mineral density at all sites .
Furthermore, one study compared the effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal women. Participants were randomized to receive either 20mg tamoxifen or 40 mg toremifene for a year. The research found that tamoxifen had a significant impact on increasing bone mineral density while toremifene didn’t influence BMD in postmenopausal women .
Toremifene has been shown to prevent prostate cancer in men at high risk. In a double-blind phase IIB clinical trial. 514 patients with prostatic intraepithelial neoplasia were randomized to receive either 20mg, 40mg and 60mg tamoxifen or placebo for 12 months. Prostatic Intraepithelial Neoplasia is characterized by pathological changes in the cell lining of the prostate gland ducts that are considered precursors to prostate cancer. The results found that the treatment decreased the incidence of prostate cancer and had a tolerability profile as compared to placebo .
Research shows that toremifene has a positive effect on lipid profile. Dyslipidemia is common in postmenopausal women, which predisposes them to cardiovascular diseases. A phase III randomized clinical trial conducted on postmenopausal women with breast cancer found that toremifene decreased low-density lipoprotein cholesterol and increased high lipoprotein cholesterol .
Furthermore, men on androgen deprivation therapy are at high risk of coronary artery disease and myocardial infarction. A treatment-related increase in lipid serum levels might contribute to a greater risk of CVD. A phase III clinical trial found that toremifene decreased low-density lipoprotein cholesterol, triglycerides, and total cholesterol and increased high-density lipoprotein cholesterol .
Toremifene is a chlorinated derivative of tamoxifen, a non-steroidal selective estrogen receptor modulator. It has been approved by the FDA for the treatment of breast cancer in postmenopausal women. It shows equivalent efficacy to tamoxifen and promising results in the treatment of prostate cancer and management of side effects related to androgen deprivation therapy. At Element Sarms, toremifene for sale is exclusively available for research and educational institutions. Only buy toremifene if you are a qualified researcher.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.